Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Cellectis S.A. ADR
(NQ:
CLLS
)
1.860
UNCHANGED
Streaming Delayed Price
Updated: 3:59 PM EST, Nov 21, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Cellectis S.A. ADR
< Previous
1
2
3
4
5
6
7
Next >
Cellectis Announces the execution of the Subsequent Investment Agreement with AstraZeneca
November 15, 2023
From
Cellectis Inc.
Via
GlobeNewswire
Cellectis Reports Financial Results for Third Quarter and First Nine Months 2023
November 06, 2023
From
Cellectis Inc.
Via
GlobeNewswire
Earnings Scheduled For November 6, 2023
November 06, 2023
Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is expected to report quarterly earnings at $0.16 per share on revenue of $366.82 million.
Via
Benzinga
Earnings Preview: Cellectis
November 03, 2023
Via
Benzinga
Cellectis to Present Preliminary Results of NATHALI_01 and Updated Results of the BALLI_01 Phases I Trials at the American Society of Hematology (ASH) 65th Annual Meeting
November 02, 2023
From
Cellectis Inc.
Via
GlobeNewswire
Why STAAR Surgical Shares Are Trading Lower By Around 16%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
November 02, 2023
Gainers OmniLit Acquisition Corp. (NASDAQ: OLIT) jumped 53.2% to $15.53. OmniLit announced that its merger with Syntec was approved by shareholders.
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
November 02, 2023
Via
Benzinga
Why Roku Shares Are Trading Higher By Around 19%; Here Are 20 Stocks Moving Premarket
November 02, 2023
Gainers LumiraDx Limited (NASDAQ: LMDX) shares surged 39.7% to $0.1143 in pre-market trading after falling 17% on Wednesday. LumiraDX recently announced the receipt of the Nasdaq delisting...
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
November 02, 2023
Pre-market stock movers are a hot topic on Thursday and we're checking out all of the biggest ones worth watching this morning!
Via
InvestorPlace
Cellectis to Report Third Quarter 2023 Financial Results on November 6, 2023
November 01, 2023
From
Cellectis Inc.
Via
GlobeNewswire
Dow Gains Over 100 Points; Fed Leaves Interest Rates Unchanged
November 01, 2023
U.S. stocks traded higher toward the end of trading, after the Federal Reserve announced its policy decision. The Dow traded up 0.40% to 33,185.41 while the NASDAQ rose 0.92% to 12,969.54. The S&P 500...
Via
Benzinga
Topics
Economy
Stocks
Exposures
Interest Rates
US Equities
12 Health Care Stocks Moving In Wednesday's Intraday Session
November 01, 2023
Via
Benzinga
Why Is Cancer Player Cellectis Stock Trading Over 100% Higher Today?
November 01, 2023
Cellectis SA (NASDAQ: CLLS) shares are trading higher after the company
Via
Benzinga
Why Extreme Networks Shares Are Trading Lower By Around 15%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
November 01, 2023
Gainers
Via
Benzinga
Nasdaq Surges Over 100 Points Ahead Of Fed Decision; WeWork Shares Plunge
November 01, 2023
U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining more than 100 points on Wednesday. The Dow traded up 0.55% to 33,233.33 while the NASDAQ rose 0.87% to 12,962.92. The...
Via
Benzinga
Topics
Economy
Stocks
Exposures
Interest Rates
US Equities
US Stocks Mixed; Private Sector Payrolls Increase Less Than Expected
November 01, 2023
U.S. stocks traded mixed this morning, ahead of interest rate decision from the Federal Reserve. Following the market opening Wednesday, the Dow traded down 0.05% to 33,036.63 while the NASDAQ rose...
Via
Benzinga
Topics
Economy
Stocks
Exposures
Interest Rates
US Equities
Why Is WeWork (WE) Stock Down 38% Today?
November 01, 2023
WeWork stock is falling on Wednesday as investors in WE shares react to reports that the company is considering a bankruptcy filing.
Via
InvestorPlace
Topics
Bankruptcy
Exposures
Financial
Legal
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
November 01, 2023
Via
Benzinga
Why Is Paycom Software (PAYC) Stock Down 39% Today?
November 01, 2023
Paycom Software stock is falling hard on Wednesday as investors in PAYC go over the company's mixed earnings report for Q3 2023!
Via
InvestorPlace
Why Is Mainz Biomed (MYNZ) Stock Moving Today?
November 01, 2023
Mainz Biomed stock is on the move Wednesday as investors in MYNZ react to results from a colorectal cancer screening test campaign.
Via
InvestorPlace
Why Is Cellectis (CLLS) Stock Up 175% Today?
November 01, 2023
Cellectis stock is taking off on Wednesday as investors in CLLS react to a massive $245 million investment from AstraZeneca.
Via
InvestorPlace
Why Plus Therapeutics Shares Are Trading Higher By Over 11%; Here Are 20 Stocks Moving Premarket
November 01, 2023
Gainers
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
November 01, 2023
We're starting off Wednesday with a breakdown of the biggest pre-market stock movers investors will want to keep track of today!
Via
InvestorPlace
Cellectis Announces Strategic Collaboration and Investment Agreements with AstraZeneca
November 01, 2023
From
Cellectis Inc.
Via
GlobeNewswire
Cellectis Presents Pre-Clinical Data on Multi-armored Allogeneic MUC1-CAR T-cells Targeting Triple-Negative Breast Cancer at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting
October 31, 2023
From
Cellectis Inc.
Via
GlobeNewswire
Cellectis to Present Pre-Clinical Data on HSPC Gene Therapy Program and Comprehensive Analysis of TALE-BE at the ESGCT 30th Annual Congress
October 24, 2023
From
Cellectis Inc.
Via
GlobeNewswire
Cellectis and Imagine Institute Publish A Proof-Of-Concept Study of a Gene Surgery Candidate to Treat Activated Phosphoinositide 3-Kinase Δ Syndrome Type 1 (APDS1)
October 12, 2023
From
Cellectis Inc.
Via
GlobeNewswire
Cellectis to Present Pre-Clinical Data on Multi-armored Allogeneic MUC1-CAR T-cells Targeting Triple-Negative Breast Cancer at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting
September 27, 2023
From
Cellectis Inc.
Via
GlobeNewswire
Cellectis Provides Full Report for Second Quarter 2023 Financial Results
August 07, 2023
From
Cellectis Inc.
Via
GlobeNewswire
Cellectis Provides Business Updates and Preliminary Financial Results for Second Quarter 2023
August 03, 2023
From
Cellectis Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.